TickerFacts.

Erasca, Inc. (ERAS): Operating Income

Annual figures by period end, from SEC filings.

-$140.91M
Year ended 2025-12-31
-$302.68M
Trailing 12 months to 2026-06-30
2020-12-31: -$109.25M2021-12-31: -$124.88M2022-12-31: -$247.45M2023-12-31: -$141.53M2024-12-31: -$179.59M2025-12-31: -$140.91M-$140.91M
2020-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$140.91Mn/m2026-03-12, From 2025-01-01
2024-12-31-$179.59Mn/m2026-03-12, From 2024-01-01
2023-12-31-$141.53Mn/m2025-03-20, From 2023-01-01
2022-12-31-$247.45Mn/m2024-03-27, From 2022-01-01
2021-12-31-$124.88Mn/m2023-03-23, From 2021-01-01
2020-12-31-$109.25Mn/a2022-03-24, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Erasca, Inc. (ERAS)2025-12-31-$140.91Mn/m
Ironwood Pharmaceuticals Inc (IRWD)2025-12-31$98.50M+5.8%
Tango Therapeutics, Inc. (TNGX)2025-12-31-$111.29Mn/m
Oncotelic Therapeutics, Inc. (OTLC)2025-12-31-$3.19Mn/m
Harrow, Inc. (HROW)2025-12-31$30.52M+245.9%
Nkarta, Inc. (NKTX)2025-12-31-$122.00Mn/m
MBX Biosciences, Inc. (MBX)2025-12-31-$98.06Mn/m
Oric Pharmaceuticals, Inc. (ORIC)2025-12-31-$143.00Mn/m
Zenas BioPharma, Inc. (ZBIO)2025-12-31-$383.06Mn/m

Compare ERAS, IRWD, TNGX, OTLC side by side · Screen every company in Pharmaceutical Preparations ↗